Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 6,618 shares at $76.95 ($512K) on 2026-01-06, disclosed to the SEC on 2026-01-08.
Seasonal sale ($512k) by Executive VP AND CLO — this insider has traded PTCT in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $76.95 | 1,739 | $134K | 26.2% |
| 2 | $77.10 | 471 | $36K | 7.1% |
| 3 | $77.11 | 1,638 | $126K | 24.7% |
| 4 | $77.48 | 1,503 | $116K | 22.8% |
| 5 | $77.91 | 949 | $74K | 14.5% |
| 6 | $77.92 | 269 |
| $21K |
| 4.1% |
| 7 | $78.60 | 38 | $3K | 0.6% |
| 8 | $78.98 | 11 | $869 | 0.2% |
| Total | $77.31 avg | 6,618 | $512K | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |